Jiangsu Jibeier Pharmaceutical (688566) Q3 2025 earnings summary

Executive summary

• Revenue for the first nine months reached RMB 704.43 million, up 9.52% year-over-year.

• Net profit attributable to shareholders for the same period was RMB 196.90 million, a 12.80% increase year-over-year.

• Q3 net profit declined 9.45% year-over-year, while Q3 revenue grew 19.08%.

Financial highlights

• Operating income for the first nine months was RMB 704.43 million, up from RMB 643.21 million year-over-year.

• Net profit for the first nine months was RMB 195.86 million, compared to RMB 174.31 million year-over-year.

• Basic and diluted EPS for the first nine months was RMB 0.99, up 8.79% year-over-year.

• Gross margin and operating margin details not explicitly provided.

Outlook and guidance

• No explicit forward-looking guidance or projections for future quarters provided.